Cancer patients suffer high levels of affective and cognitive disturbances, which have been attributed to diagnosis-related distress, impairment of quality of life, and side effects of primary treatment. An inflammatory microenvironment is also a feature of the vast majority of solid tumors. However, the ability of tumor-associated biological processes to affect the central nervous system (CNS) has only recently been explored in the context of symptoms of depression and cognitive disturbances. In this review, we summarize the burgeoning evidence from rodent cancer models that solid tumors alter neurobiological pathways and subsequent behavioral processes with relevance to affective and cognitive disturbances reported in human cancer populations. We consider, in parallel, the evidence from human clinical cancer research demonstrating that affective and cognitive disturbances are common in some malignancies prior to diagnosis and treatment. We further consider the underlying neurobiological pathways, including altered neuroinflammation, tryptophan metabolism, prostaglandin synthesis and associated neuroanatomical changes, that are most strongly implicated in the rodent literature and supported by analogous evidence from human cancer populations. We focus on the implications of these findings for behavioral researchers and clinicians, with particular emphasis on methodological issues and areas of future research.
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Introduction
Cancer patients suffer from a high prevalence of depression, anxiety, and cognitive disturbances (Evans et al., 2005) . In fact, these disturbances are common among numerous other populations with chronic, inflammatory disease (e.g, cardiovascular disease, metabolic disease, HIV/AIDS), a fact that has stimulated discussion of potential shared biological mechanisms (Irwin and Miller, 2007; Lee et al., 2004) . In the field of cancer research, it is widely acknowledged that various interrelated factors may underlie these behavioral comorbidities: tumor biology, distress associated with the cancer diagnosis, and/or cancer treatments (e.g., ''chemobrain''). However, in spite of a recent burst of research activity in this area, these factors are rarely differentiated and their likely mechanistic interactions remain either entangled or ignored (Dantzer et al., 2012) . For example, many clinical cancer studies do not encompass pre-diagnosis or pre-treatment psychological or physiological measures and most rodent studies of the impact of cancer treatment on the central nervous system (CNS) use tumor-free models. This results in a knowledge gap concerning the independent impact of tumor-associated biological processes on affective and cognitive symptoms despite the acknowledgment that tumors are capable of exerting an influence on the CNS (Cleeland et al., 2003; Lee et al., 2004) , and that inflammation is inherent to all phases of tumor growth and metastases (Colotta et al., 2009) . Addressing this deficit will help to identify specific underlying biological causes and mechanisms of cancer-associated affective and cognitive disturbances, with the potential to improve treatment.
This knowledge gap by presenting the current literature on the potential for tumor-associated biological processes to affect brain function (affect and cognition) independent of cancer-associated stress and treatments. We focus on behavioral changes that are most strongly associated with the presence of a tumor outside of the CNS and on identifying underlying mechanisms using data
